PLANTATION, Fla. and ROCKVILLE, Md., May 17, 2011 /PRNewswire/ -- Goodwin Biotechnology, Inc. (GBI), a full service contract biomanufacturing company, and RAFAGEN, Inc., a leader in cell line engineering for protein and monoclonal antibody drug production, jointly announced their collaborative agreement for cell line engineering and biological contract manufacturing.
"We seek to address unmet needs of patients with inherited and acquired diseases," said Sung Ho Hahm, PhD, co-founder and President / CEO of RAFAGEN. "With RAFAGEN's proprietary technology platforms, the highest producing cell lines will be established at a fraction of the time currently required. This translates the promise of science into tangible therapies that restore health and save lives."
"By collaborating with RAFAGEN for cell line engineering, we at GBI can expand our capabilities as a biological contract manufacturing organization and offer one-stop shopping," noted SooYoung Lee, PhD, Senior Vice President at GBI. "This enables our clients to overcome challenging projects by working from their cDNA to develop more robust and high productivity cell lines that will not only scale up with greater efficiency, but by identifying cell lines with the highest level of efficacy, the end product will hopefully optimize patient outcomes."
About Goodwin Biotechnology, Inc.
Goodwin Biotechnology is a fully integrated cGMP contract manufacturer of monoclonal antibodies, recombinant proteins and vaccines GBI has the expertise and experience in development and GMP manufacturing of recombinant proteins and antibody drug conjugates (e.g. antibodies conjugated to linkers for radio immune therapy and diagnostics, other antibodies, proteins, chemotoxins, or plant toxins). GBI also offers process development services from proof of concept and preclinical through phase II clinical studies. With nearly 20 years of experience as an independent contract manufacturer, GBI has worked with companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established biopharmaceutical companies.
About RAFAGEN, Inc.
RAFAGEN's primary focus is on the development and commercialization of next generation gene expression systems, with applications in solving the most challenging problems in molecular therapeutics. In the field of recombinant protein and monoclonal antibody therapeutics, RAFAGEN's technology will facilitate a marked increase in drug production from manufacturing facilities. Protein drugs will be launched in the market and revenue will be generated at a faster rate than ever before. In this rapidly emerging and highly competitive market, companies applying RAFAGEN's state-of-the-art technologies will amass unparalleled selective advantages.
For more information, please contact:
Goodwin Biotechnology: (954) 327-9639; firstname.lastname@example.org
RAFAGEN: (301) 309-1601; email@example.com
SOURCE Goodwin Biotechnology, Inc.